DiaMedica Therapeutics: Of This Current Report On Form 8k Is Hereby Incorporated By Reference Into This Item 3.02. Based In Part On The Representations Of The Purchasers In The Securities Purchase Agreement, The Offering And Sale Of The Shares Will Be Exempt From Registration Under Section 4(a)(2) Of The United States Securities Act Of 1933, As Amended (the “securities Act”), And Rule 506 Of Regulation D As Promulgated Thereunder. The Sale Of The Shares Did Not Involve A Public Offering And Was Made Without General Solicitation Or General Advertising. The Purchasers Have Represented That They Are Accredited Investors, As Such Term Is Defined In Rule 501(a) Of Regulation D Under The Securities Act, And They Are Acquiring The Shares For Investment Purposes Only And Not With A View To Any Resale, Distribution Or Other Disposition Of The Shares In Violation Of The United States Federal Securities Laws, Other Events, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  DiaMedica Therapeutics Inc.
• Registration country
  Canada
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***